{'fraction_non_alphanumeric': 0.014657980456026058, 'fraction_numerical': 0.003257328990228013, 'mean_word_length': 6.151162790697675, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
New therapeutic approaches in uveitis

Purpose Autoimmune uveitis is a severe disease, responsible for approximately 10% of acquired blindness. The side effects induced by systemic steroids or immunosuppressive therapies have prompted us to search for more specific treatments. Recently, tyrosine kinase inhibitors, including imatinib and sunitinib, have shown interesting properties in several autoimmune diseases. Their immunomodulating properties make them potential interest in the treatment of autoimmune uveitis and we analyzed their therapeutic effects in the mouse model of experimental autoimmune uveitis.